Cargando…

Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial

BACKGROUND: Major depressive disorder (MDD) is a highly prevalent, heterogeneous and systemic medical condition. Treatment options are limited, and recent studies have suggested that physical exercise can play an important role in the therapeutics of MDD. The aim of this study was to evaluate the an...

Descripción completa

Detalles Bibliográficos
Autores principales: Siqueira, Cristiana Carvalho, Valiengo, Leandro L., Carvalho, André F., Santos-Silva, Paulo Roberto, Missio, Giovani, de Sousa, Rafael T., Di Natale, Georgia, Gattaz, Wagner F., Moreno, Ricardo Alberto, Machado-Vieira, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859497/
https://www.ncbi.nlm.nih.gov/pubmed/27152523
http://dx.doi.org/10.1371/journal.pone.0154195
Descripción
Sumario:BACKGROUND: Major depressive disorder (MDD) is a highly prevalent, heterogeneous and systemic medical condition. Treatment options are limited, and recent studies have suggested that physical exercise can play an important role in the therapeutics of MDD. The aim of this study was to evaluate the antidepressant efficacy of adjunctive aerobic activity in association with pharmacotherapy (selective serotonin reuptake inhibitor) in symptomatic MDD as well as its association with physiological biomarkers. METHODS: In this randomized, single-blind, add-on, controlled clinical trial, 57 patients (18–55 years of age) were followed-up for 28 days. All patients were drug-free, had been diagnosed with symptomatic MDD and received flexible dose of sertraline during the trial. Patients were randomized to either a 4-week program (4x/week) of add-on aerobic exercise (exercise group, N = 29) or no activity (control group, N = 28). Depression severity was assessed using the Hamilton Rating Scale for Depression (HAM-D) as the primary outcome. At baseline and endpoint, all patients underwent a comprehensive metabolic/cardiopulmonary exercise testing—including determination of maximal oxygen uptake (VO(2)max), VO(2) at the second ventilatory threshold (VO(2)-VT2), and oxygen pulse (O(2) pulse). RESULTS: Depression scores significantly decreased in both groups after intervention. Importantly, patients in the aerobic exercise group required lower sertraline dose compared to the control group (sertraline monotherapy). The VO(2)max and O(2) pulse parameters increased over time only in the exercise group and remained unchanged in the control group. CONCLUSIONS: The present findings suggest that a 4-week training of aerobic exercise significantly improves functional capacity in patients with MDD and may be associated with antidepressant efficacy. This approach may also decrease the need for higher doses of antidepressants to achieve response. Further studies in unmedicated and treatment-resistant MDD patients are needed in order to confirm the utility of short-term aerobic exercise as an alternative therapeutic approach in MDD. TRIAL REGISTRATION: ClinicalTrials.gov NCT02427789